Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

EyePoint, Inc. Common Stock

EYPT

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Last trade $0.3162
Day change +$0.0086 (+2.80%)
Day range $0.292 – $0.32
Volume 1,853,194
Market cap $35M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$35.27M
Price / earnings
—
Price / book
0.33×
Price / sales
13.68×
EV / sales
-18.59×
EV / EBITDA
0.14×

Profitability

Earnings per share
-$3.01
Return on assets
-206.26%
Return on equity
-315.82%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.3×
Quick ratio
3.25×
Cash ratio
2.16×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$299.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EYPT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$756K$507K$696K$620K$966K$5.33M$24.45M$11.59M
Cost of revenue$523K$0$528K$375K$721K$165K$805K$816K
Gross profit$233K$507K$168K$245K$245K$5.17M$23.65M$10.77M
Selling, general and administrative$15.44M$14.27M$15.25M$11.38M$14.52M$11.9M$13.91M$12.64M
Research and development$81.67M$83.61M$72.15M$59.21M$47.75M$55.5M$58.57M$43.37M
Total operating expenses$97.11M$97.89M$87.39M$70.59M$62.27M$67.4M$72.49M$56.01M
Operating income-$96.88M-$97.38M-$87.23M-$70.35M-$62.03M-$62.23M-$48.84M-$45.24M
Interest expense$0$0$0-$33K$0$0$0-$14K
Income before taxes-$95.61M-$94.47M-$84.88M-$67.42M-$59.73M-$59.33M-$45.2M-$41.31M
Income taxes$0$0-$50K$186K$0$93K$0$90K
Net income-$95.61M-$94.47M-$84.83M-$67.61M-$59.73M-$59.43M-$45.2M-$41.4M
Net income attributable to common shareholders-$95.61M-$94.47M-$84.99M-$67.61M-$59.73M-$59.43M-$45.3M-$41.4M
EBITDA-$96.11M-$96.69M-$86.59M-$69.65M-$61.45M-$61.69M-$48.34M-$44.77M
Basic earnings per share-$1.07-$1.09-$0.99-$0.81-$0.85-$0.85-$0.65-$0.64
Diluted earnings per share-$1.07-$1.09-$0.99-$0.81-$0.85-$0.85-$0.65-$0.64

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates

EyePoint (EYPT) reported a quarterly loss of $1.07 per share, missing the consensus estimate of $0.88, representing a -21.59% earnings surprise. The company's stock has declined 98.1% year-to-date versus the S&P 500's 11.3% gain. Despite beating revenue estimates, the company maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions. AnaptysBio (ANAB), a peer in the Medical - Biomedical and Genetics industry, is expected to report earnings of $0.41 per share with revenues down 58% year-over-year.

Zacks Investment Research

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Oculis Holding AG is expected to report a quarterly loss of $0.49 per share with revenues of $0.29 million for Q3 2026. However, the company has a positive Earnings ESP of +3.09% combined with a Zacks Rank #2 (Buy), suggesting it will likely beat consensus EPS estimates. The company previously delivered a significant earnings surprise of +58.33% in the last quarter.

Zacks Investment Research

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

EyePoint (EYPT) is expected to report a quarterly loss of $0.88 per share with revenues down 79.4% year-over-year for Q3 2026. However, the stock shows a positive Earnings ESP of +2.86% combined with a Zacks Rank #3, suggesting a likely earnings beat. The company has a poor track record, missing consensus estimates in the last four quarters. Liquidia Corporation (LQDA) is also discussed as an industry peer with a negative ESP and Strong Sell rating.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the failure of its DURAVYU drug candidate to meet primary efficacy endpoints in two Phase 3 clinical trials (LUGANO and LUCIA) for wet AMD treatment. The company's stock plummeted 66.98% on August 17, 2026, and an additional 85.28% on October 19, 2026, following the disappointing results. EyePoint announced significant cost-cutting measures including a 53% workforce reduction and termination of its wet AMD clinical program.

GlobeNewswire Inc.

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

EyePoint announced that LUCIA, its second Phase 3 clinical trial of DURAVYU for wet AMD treatment, failed to meet its primary endpoint of non-inferiority in visual acuity versus aflibercept control. However, the drug demonstrated visual improvement and met key secondary endpoints including a 38% reduction in treatment burden and strong anatomic control. The company plans to conduct additional analyses and remains focused on its Phase 3 DME program with data expected in Q4 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 9, 20201-for-10reverse split